Keyphrases
Transcript Expression
96%
Transcription Initiation
96%
SNRPN
96%
Late-stage Cancer
96%
Imprinting Center
96%
RNA Polymerase II (RNAPII)
96%
MRNA 3′ End Processing
96%
Histone H3 Lysine 27
96%
Small nuclear Ribonucleoprotein (snRNP)
96%
Multifocal Disease
96%
ABCC11
96%
Earwax
96%
Human Promoter
96%
GRB10
96%
Molecular Heterogeneity
96%
Melanoma Brain Metastases
96%
Molecular Tumor Board
72%
Normal Urothelium
64%
RNA Exosome
48%
Eukaryotic Genomes
48%
Activity-dependent Gene Expression
48%
Tiling Microarray
48%
Regulatory Potential
48%
DNA Methyltransferase 3B (DNMT3B)
48%
Differentially Methylated Regions
48%
Transcriptome Map
48%
TFIIB
48%
UV Treatment
48%
UV Analysis
48%
Mammalian Proteins
48%
Downstream Genes
48%
Promoter Binding
48%
Gene Activity
48%
Polyadenylation Sites
48%
Polycomb Group (PcG) Proteins
41%
Tumorigenic Transformation
32%
Acquired mutations
32%
Low-frequency mutation
32%
Deep Resequencing
32%
Intratumor
32%
CheckMate
32%
Transcription Cycle
24%
3′ End Processing
24%
Readthrough
24%
Gene Body
24%
3′ End Formation
24%
Functional Coupling
24%
RNA Maturation
24%
End-stage Cancer
24%
Druggability
24%
Biochemistry, Genetics and Molecular Biology
Methylation
96%
Single Nucleotide Polymorphism
96%
Exome Sequencing
96%
Mouse
96%
Allele
96%
Small Nuclear Ribonucleoprotein Polypeptide N
96%
Transcriptomics
96%
Mutation Rate
96%
DNA Methylation
96%
Histone H3
96%
Gene Mutation
96%
Differentially Methylated Regions
72%
Angelman Syndrome
72%
Germ Cell
72%
Germline
48%
Intron
48%
Enhancer Region
48%
RNA Polymerase II
40%
Polycomb-Group Proteins
28%
Exon
24%
Gene Polymorphism
24%
Genotyping
24%
Haplotype
24%
Cis Acting Element
24%
Nerve Cell Culture
24%
Somatic Cell
24%
Promoter Region
24%
RNA Degradation
24%
Transcription Termination
16%
Globin Gene
16%
DNMT3B
10%
DAP (Gene)
10%
Gene Activity
10%
Glial Cells
9%
Brain Cell Culture
9%
Medicine and Dentistry
Neoplasm
100%
Diseases
96%
Bladder Cancer
96%
Personalized Medicine
96%
Cancer Staging
96%
Targeted Therapy
96%
Malignant Neoplasm
72%
Clinical Trial
48%
Tumour Heterogeneity
27%
Prostate Cancer
24%
Tumor Biopsy
24%
Lung Cancer
24%
Biological Marker
24%
Molecular Profiling
24%
Gene Mutation
13%
Recurrent Disease
13%
Transcriptomics
13%
Mutation Rate
13%
Exome Sequencing
13%
Lymph Node Metastasis
13%